Genetic Technologies Corrects Nasdaq Non-Compliance by Naming Director | GenomeWeb
NEW YORK (GenomeWeb News) — Genetic Technologies today said it has corrected its “brief non-compliance” with the Nasdaq exchange by appointing a director and audit committee chairman.
 
The firm appointed David Carruthers, who formerly was CFO and European regional CEO for BP Finance, and was managing director of the Treasury Corporation of Victoria, Australia.
 
Carruthers also serves on the audit committee for Ceramic Fuel Cells and is a non-executive director for India Equities Fund.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.